New trials, publications, preprints and grants on this target, month by month.
Trial
Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
1 Mar 2027· NA · NOT_YET_RECRUITING· CTGOV
Trial
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Assessment of genomic instability and homologous recombination repair in ovarian cancer using the Oncomine Comprehensive Assay Plus.
5 Nov 2026· Oncotarget· PUBMED
Publication
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study.
3 Nov 2026· JCO precision oncology· PUBMED
Publication
Impact of BRCA2, BRCA1, and Other Individual Homologous Recombination Repair Alterations on Survival in Metastatic Castration-resistant Prostate Cancer.
3 Nov 2026· European urology oncology· PUBMED
Trial
First-in-Human, Multicenter, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of YL-18319 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors
30 Oct 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
The effect of germline mutations on survival outcomes of breast cancer - Study from a tertiary care center in North India.
29 Oct 2026· Journal of cancer research and therapeutics· PUBMED
Publication
Germline BRCA-Lynch syndrome MINAS: report of six Argentinian families and a systematic review of the literature.
28 Oct 2026· Familial cancer· PUBMED
Publication
BRCA1 Mutation-Recognizing Tetrahedral Framework Nucleic Acid Nanoplatform Enables Coordinated PARP/WEE1 Inhibition and STING-Associated Antitumor Immunity in Ovarian Cancer.
28 Oct 2026· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publication
Multi-omics analysis of high-grade serous ovarian cancers reveals heterogeneity and distinct immunological patterns based upon clinico-genomic status.
22 Oct 2026· PLoS genetics· PUBMED
Publication
Correlation between BRCA mutational status and lymph node metastasis in advanced epithelial ovarian cancer: a retrospective study.
20 Oct 2026· PeerJ· PUBMED
Publication
BRCA1 Promoter Methylation Marks a Shared Blood Methylome State in Women with and Without Breast Cancer.
19 Oct 2026· International journal of molecular sciences· PUBMED
Publication
Occult serous tubal intraepithelial carcinoma and high-grade serous carcinoma at risk-reducing salpingo-oophorectomy in BRCA1/2 carriers: A Czech two-center cohort.
19 Oct 2026· International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics· PUBMED
Publication
Cancer risks associated with BRCA1 and BRCA2: Overview and management.
15 Oct 2026· Cancer· PUBMED
Publication
A urothelial cell carcinoma in the abdominal cavity after salpingectomy for tubo-ovarian carcinoma risk reduction in a BRCA1 pathogenic variant carrier.
14 Oct 2026· Gynecologic oncology reports· PUBMED
Publication
Large-scale integration of functional assay data for the resolution of germline BRCA1 and BRCA2 variants of uncertain significance.
12 Oct 2026· American journal of human genetics· PUBMED
Publication
Somatic panel testing reveals no common alternative oncogenic driver in BRCA1/2-mutant high-grade serous ovarian cancer with discordant low genomic instability score.
8 Oct 2026· Journal of medical genetics· PUBMED
Publication
Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study.
8 Oct 2026· Nature communications· PUBMED
Publication
Case Report: Coexpression of somatic EGFR, BRCA1, and BRCA2 mutations in metastatic non-small cell lung cancer.
8 Oct 2026· Frontiers in oncology· PUBMED
Publication
Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study.
6 Oct 2026· European urology· PUBMED
Trial
Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants
1 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
BRCA1/2 Carriers With Breast-Ovarian Double Primary Cancers Versus Ovarian Cancer Alone: Mutation Profiles and Survival Outcomes.
1 Oct 2026· International journal of cancer· PUBMED
Publication
Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2: A Network Meta-Analysis.
1 Oct 2026· JAMA network open· PUBMED
Publication
Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer.
1 Oct 2026· Cancer research communications· PUBMED
Publication
Radiogenomic Analysis of Contrast-Enhanced MRI for Predicting Pathogenic BRCA Variants in Ovarian Cancer.
1 Oct 2026· Acta medica Okayama· PUBMED
Publication
Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.
1 Oct 2026· The Journal of clinical investigation· PUBMED
Preprint
Cell-of-origin shapes tumor subtype in BRCA1 -associated triple-negative breast cancer.
30 Sept 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer.
29 Sept 2026· Critical reviews in oncology/hematology· PUBMED
Publication
Risk-reducing salpingo-oophorectomy in patients with gBRCA-mutated breast cancer.
28 Sept 2026· Archives of gynecology and obstetrics· PUBMED
Publication
Clinical impact of ENIGMA-based variant reclassification on genotype-phenotype analyses in BRCA1- and BRCA2-associated hereditary breast and ovarian cancer.
25 Sept 2026· Breast cancer (Tokyo, Japan)· PUBMED